Jiangsu Bioperfectus Technologies Co., Ltd.

Shanghai Stock Exchange 688399.SS

Jiangsu Bioperfectus Technologies Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 479.61 M

Jiangsu Bioperfectus Technologies Co., Ltd. Shareholders' Equity is USD 479.61 M for the year ending December 31, 2023, a -12.40% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Jiangsu Bioperfectus Technologies Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 547.49 M, a 37.15% change year over year.
Jiangsu Bioperfectus Technologies Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 399.19 M, a 56.54% change year over year.
Jiangsu Bioperfectus Technologies Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 255.00 M, a 73.96% change year over year.
Jiangsu Bioperfectus Technologies Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 146.59 M, a 211.06% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Shanghai Stock Exchange: 688399.SS

Jiangsu Bioperfectus Technologies Co., Ltd.

CEO	Dr. Guoqiang Wang
IPO Date	Dec. 5, 2019
Location	China
Headquarters	Block G19 1
Employees	684
Sector	Healthcare
Industries Biotechnology 3D Printing Cleaning Supplies Clinical Trials Hardware & Electronics Medical Instruments Personal Care Pharmaceuticals

Description

Jiangsu Bioperfectus Technologies Co., Ltd. researches and develops, produces, and sells in vitro diagnostic products in China. It offers in vitro diagnostic reagents and supporting detectors, as well as in vitro testing services. The company was founded in 2010 and is based in Taizhou, China.

Key trends

Past 5 years